f FB-401 failed to the meet primary endpoint in atopic dermatitis. Consequently, Forte is discontinuing the development of FB-401. As FB-401 was the company's only asset, Nakae expects management to "quickly take the necessary steps to reduce cash burn." The analyst believes that options going forward include utilizing the remaining cash to acquire a new early stage asset to develop, or becoming a shell that another private company can reverse into.
hat FB-401 failed to meet statistical significance for primary endpoint in an atopic dermatitis trial and will be discontinued. Raja sees "little value left" and expects the stock to trade close to cash, the analyst tells investors
cash is under $3